| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.5 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.045 | 0.5 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.5 |